CVS Caremark settles meth investigation
SAN FRANCISCO (Reuters) - A CVS Caremark Corp subsidiary agreed to pay $77.6 million to settle an investigation that it unlawfully sold a key ingredient to manufacture methamphetamine, the U.S. Attorney in Los Angeles said on Thursday.
CVS Pharmacy Inc admitted it sold pseudoephedrine to criminals who used it to make the drug, according to the U.S. Attorney's office. CVS eventually changed its practices to prevent the sales after it became aware of the investigation, the government said in its statement.
In a statement on Thursday, CVS called the sales an "unacceptable breach" of company policy and "totally inconsistent with our values."
CVS agreed to pay a $75 million civil penalty and forfeit $2.6 million in profits from the illegal sales.
The government said it will not pursue criminal charges against CVS, and the company will implement a compliance and ethics program.
CVS Caremark shares were down 2.1 percent to $30.98 in late New York Stock Exchange trading.
(Reporting by Dan Levine, Editing by Peter Henderson and Gerald E. McCormick)
- Insight: How U.S. spying cost Boeing multibillion-dollar jet contract
- Exclusive: Secret contract tied NSA and security industry pioneer |
- With Fed out of the way, what's next on Wall Street?
- Insight: For Chinese farmers, a rare welcome in Russia's Far East
- Analysis: Lost Brazil order raises threat to Boeing fighter jets
A federal judge struck down Utah's ban on same-sex marriage as unconstitutional, handing a major victory to gay rights activists in a conservative state Slideshow